West Nile and St. Louis encephalitis viruses

Handbook of Clinical Neurology

Volumn 123, Issue , 2014, Pages 433-447

  Oyer, Ryan J ^a   Beckham, J David ^a   Tyler, Kenneth L ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Acute flaccid paralysis; Encephalitis; Meningitis; Poliomyelitis; St. Louis encephalitis virus; West Nile virus

Indexed keywords

ACUTE FLACCID PARALYSIS; ANIMAL; ARTICLE; ENCEPHALITIS; HUMAN; MENINGITIS; PATHOGENICITY; POLIOMYELITIS; ST LOUIS FLAVIVIRUS; ST. LOUIS ENCEPHALITIS; ST. LOUIS ENCEPHALITIS VIRUS; WEST NILE FEVER; WEST NILE FLAVIVIRUS;

ACUTE FLACCID PARALYSIS; ENCEPHALITIS; MENINGITIS; POLIOMYELITIS; ST. LOUIS ENCEPHALITIS VIRUS; WEST NILE VIRUS;

ANIMALS; ENCEPHALITIS VIRUS, ST. LOUIS; ENCEPHALITIS, ST. LOUIS; HUMANS; WEST NILE FEVER; WEST NILE VIRUS;

EID: 84903998306     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-53488-0.00020-1     Document Type: Chapter

References (130)

1. Ali M., Safriel Y., Sohi J., et al. West Nile virus infection: MR imaging of the neurvous system. AJNR Am J Neuroradiol 2005, 26:289-297.
2. Al-Shekhlee A., Katirji B. Electrodiagnostic features of acute paralytic poliomyelitis associated with West Nile infection. Muscle Nerve 2004, 29:376-380.
3. Anderson J.F., Rahal J.J. Efficacy of interferon alpha-2b and ribavirin against West Nile virus in vitro. Emerg Infect Dis 2002, 8:107-108.
4. Bai F., Wang T., Pal U., et al. Use of RNA interference to prevent lethal murine West Nile virus infection. J Infect Dis 2005, 191:1148-1154.
5. Bai F., Town T., Pradhan D., et al. Antiviral peptides targeting the West Nile virus envelope protein. J Virol 2007, 81:2047-2055.
6. Bai F., Kong K.F., Dai J., et al. A paradoxical role for neutrophils in the pathogenesis of West Nile virus. J Infect Dis 2010, 202:1804-1812.
7. Bains H.S., Jampol L.M., Caughron M.C., et al. Vitritis and chorioretinitis in a patient with West Nile virus infection. Arch Ophthalmol 2003, 121:205-207.
8. Batuello J.T., Youngwerth J., Gabel R. Increased serum lipase in west Nile virus infection. N Engl J Med 2005, 352:420-421.
9. Ben-Nathan D., Gershoni-Yahalom O., Samina I., et al. Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection. BMC Infect Dis 2009, 9:18.
10. Biedenbender R., Bevilacqua J., Gregg A.M., et al. Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults. J Infect Dis 2011, 203:75-84.
11. Bode A.V., Sejvar J.J., Pape W.J., et al. West Nile virus disease: a descriptive study of 228 patients hospitalized in a 4-county region of Colorado in 2003. Clin Infect Dis 2006, 42:1234-1240.
12. Brilla R., Block M., Geremia G., et al. Clinical and neuroradiologic features of 39 cases of West Nile virus meningoencephalitis. J Neurol Sci 2004, 220:37-40.
13. Brinker K., Monath T. The acute disease. St. Louis encephalitis 1980, 503-534. American Public Health Associates, Washington. T. Monath (Ed.).
14. Campbell G.L., Marfin A.A., Lanciotti R.S., et al. West Nile virus. Lancet Infect Dis 2002, 2:519-529.
15. Carson P.J., Konewko P., Wold K.S., et al. Long-term clinical and neuropsychological outcomes of West Nile virus infection. Clin Infect Dis 2006, 43:723-730.
16. Centers for Disease Control and Prevention Outbreak of West Nile-like viral encephalitis - New York, 1999. MMWR Morb Mortal Wkly Rep 1999, 48:845-849.
17. Centers for Disease Control and Prevention Update: West Nile-like viral encephalitis - New York, 1999. MMWR Morb Mortal Wkly Rep 1999, 48:890-892.
18. Centers for Disease Control and Prevention Possible West Nile virus transmission to an infant through breast-feeding - Michigan, 2002. MMWR Morb Mortal Wkly Rep 2002, 51:877-878.
19. Centers for Disease Control and Prevention Possible dialysis-related West Nile virus transmission - Georgia, 2003. MMWR Morb Mortal Wkly Rep 2004, 53:738-739.
20. Chowers M.Y., Lang R., Nassar F., et al. Clinical characteristics of the West Nile fever outbreak, Israel, 2000. Emerg Infect Dis 2001, 7:675-678.
21. Ciota A.T., Koch E.M., Willsey G.G., et al. Temporal and spatial alterations in mutant swarm size of St. Louis encephalitis virus in mosquito hosts. Infect Genet Evol 2011, 11:460-468.
22. Cook R.L., Xu X., Yablonsky E.J., et al. Demographic and clinical factors associated with persistent symptoms after West Nile virus infection. Am J Trop Med Hyg 2010, 83:1133-1136.
23. Cunha B.A., Minnaganti V., Johnson D.H., et al. Profound and prolonged lymphocytopenia with West Nile encephalitis. Clin Infect Dis 2000, 31:1116-1117.
24. Dai J., Wang P., Bai F., et al. Icam-1 participates in the entry of West Nile virus into the central nervous system. J Virol 2008, 82:4164-4168.
25. Davis L.E., Debiasi R., Goade D.E., et al. West Nile virus neuroinvasive disease. Ann Neurol 2006, 60:286-300.
26. Davis L.E., Beckham J.D., Tyler K.L. North American encephalitic arboviruses. Neurol Clin 2008, 26:727-757.
27. Deas T.S., Bennett C.J., Jones S.A., et al. In vitro resistance selection and in vivo efficacy of morpholino oligomers against West Nile virus. Antimicrob Agents Chemother 2007, 51:2470-2482.
28. Debiasi R.L., Tyler K.L. West Nile virus meningoencephalitis. Nat Clin Pract Neurol 2006, 2:264-275.
29. Diamond M.S. Progress on the development of therapeutics against West Nile virus. Antiviral Res 2009, 83:214-227.
30. Diamond M.S., Shrestha B., Marri A., et al. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol 2003, 77:2578-2586.
31. Diamond M.S., Sitati E., Friend L., et al. Induced IgM protects against lethal West Nile virus infection. J Exp Med 2003, 198:1-11.
32. Dohm D.J., Sardelis M.R., Turell M.J. Experimental vertical transmission of West Nile virus by Culex pipens (Diptera: Culicidae). J Med Entomol 2002, 39:640-644.
33. Ferguson D.D., Gershman K., LeBailly A., et al. Characteristics of the rash associated with West Nile Virus fever. Clin Infect Dis 2005, 41:1204.
34. Fratkin J.D., Leis A.A., Stokic D.S., et al. Spinal cord neuropathology in human West Nile virus infection. Arch Pathol Lab Med 2004, 128:533-537.
35. Freifeld A.G., Meza J., Schweitzer B., et al. Seroprevalence of West Nile virus infection in solid organ transplant recipients. Transpl Infect Dis 2010, 12:120-126.
36. Gandelman-Marton R., Kimiagar I., Itzhaki A., et al. Electroencephalography findings in adult patients with West Nile virus-associated meningitis and meningoencephalitis. Clin Infect Dis 2003, 37:1573-1578.
37. Garg S., Jampol L.M. Systemic and intraocular manifestations of West Nile virus infection. Surv Ophthalmol 2005, 50:3-13.
38. Georges A.J., Lesbordes J.L., Georges-Courbot M.C., et al. Fatal hepatitis from West Nile virus. Ann Inst Pasteur Virol 1988, 138:237.
39. Girard Y.A., Klingler K.A., Higgs S. West Nile virus dissemination and tissue tropisms in orally infected Culex pipiens quinquefasciatus. Vector Borne Zoonotic Dis 2004, 4:109-122.
40. Girard Y.A., Popov V., Wen J., et al. Ultrastructural study of West Nile virus pathogenesis in Culex pipens quinquefasciatus (Diptera: Culicidae). J Med Entemol 2005, 42:429-444.
41. Gyure K.A. West Nile virus infections. J Neuropathol Exp Neurol 2009, 68:1053-1060.
42. Haley M., Retter A.S., Fowler D., et al. The role for intravenous immunoglobulin in the treatment of West Nile virus encephalitis. Clin Infect Dis 2003, 37:e88-e90.
43. Hamdan A., Green P., Mendelson E., et al. Possible benefit of intravenous immunoglobulin therapy in a lung transplant recipient with West Nile virus encephalitis. Transpl Infect Dis 2002, 4:160-162.
44. Hayes E.B., Gubler D.J. West Nile virus: epidemiology and clinical features of an emerging epidemic in the United States. Annu Rev Med 2006, 57:181-194.
45. Hinckley A.F., O'Leary D.R., Hayes E.B. Transmission of West Nile virus through human breast milk seems to be rare. Pediatrics 2007, 119:e666-e671.
46. Hogrefe W.R., Moore R., Lape-Nixon M., et al. Performance of immunoglobulin G (IgG) and IgM enzyme-linked immunosorbent assays using a West Nile virus recombinant antigen (preM/E) for detection of West Nile virus- and other flavivirus-specific antibodies. J Clin Microbiol 2004, 42:4641-4648.
47. Huhn G.D., Dworkin M.S. Rash as a prognostic factor in West Nile virus disease. Clin Infect Dis 2006, 43:388.
48. Iwamoto M., Jernigan D.B., Guasch A., et al. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med 2003, 348:2196-2203.
49. Jean C.M., Honarmand S., Louie J.K., et al. Risk factors for West Nile virus neuroinvasive disease, California, 2005. Emerg Infect Dis 2007, 13:1918-1920.
50. Jeha L., Sila C., Lederman R., et al. West Nile virus infection. A new acute paralytic illness. Neurology 2003, 61:55-59.
51. Kalil A.C., Devetten M.P., Singh S., et al. Use of interferon-alpha in patients with West Nile encephalitis: report of 2 cases. Clin Infect Dis 2005, 40:764-766.
52. Khosla J.S., Edelman M.J., Kennedy N., et al. West Nile virus presenting as opsoclonus-myoclonus cerebellar ataxia. Neurology 2005, 64:1095.
53. Klee A.L., Maidin B., Edwin B., et al. Long-term prognosis for clinical West Nile virus infection. Emerg Infect Dis 2004, 10:1405-1411.
54. Kleinschmidt-DeMasters B.K., Marder B.A., Levi M.E., et al. Naturally acquired West Nile virus encephalomyelitis in transplant recipients: clinical, laboratory, diagnostic, and neuropathological features. Arch Neurol 2004, 61:1210-1220.
55. Komar N., Langevin S., Hinten S., et al. Experimental infection of North American birds with New York 1999 strain of West Nile virus. Emerg Infect Dis 2003, 9:311-322.
56. Kramer L.D., Li J., Shi P.Y. West Nile virus. Lancet Neurol 2007, 6:171-181.
57. Lanciotti R.S., Roehrig J.T., Deubel V., et al. Origin of the West Nile virus responsible for an outbreak of encephalitis in the Northeastern United States. Science 1999, 286:2333-2337.
58. Lanciotti R.S., Kerst A.J., Nasci R.S., et al. Rapid detection of West Nile virus from human clinical specimens, field collected mosquitoes, and avian samples by a TaqMan reverse transcriptase-PCR assay. J Clin Microbiol 2000, 38:4066-4071.
59. Leis A., Stokic D., Webb R., et al. Clinical spectrum of muscle weakness in human West Nile virus infection. Muscle Nerve 2003, 28:302-308.
60. Levi M.E., Quan D., Ho J.T., et al. Impact of rituximab-associated B-cell defects on West Nile virus meningoencephalitis in solid organ transplant recipients. Clin Transplant 2010, 24:223-228.
61. Lewis M., Amsden J.R. Successful treatment of West Nile virus infection after approximately 3 weeks into the disease course. Pharmacotherapy 2007, 27:455-458.
62. Li J., Loeb J.A., Shy M.E., et al. Asymmetric flaccid paralysis: a neuromuscular presentation of West Nile virus infection. Ann Neurol 2003, 53:703-710.
63. Lim J.K., Louie C.Y., Glaser C., et al. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. J Infect Dis 2008, 197:262-265.
64. Loeb M., Hanna S., Nicolle L., et al. Prognosis after West Nile virus infection. Ann Intern Med 2008, 149:232-241.
65. Lustig S., Halevy M., Ben Nathan D., et al. The role of host immunocompetence in neuroinvasion of Sindbis virus. Arch Virol 1999, 144:1159-1171.
66. Malkinson M., Banet C., Weisman Y., et al. Introduction of West Nile virus in the Middle East by migrating white Storks. Emerg Infect Dis 2002, 8:392-397.
67. Medarov B.I., Multz A.S., Brown W., et al. West Nile meningoencephalitis and rhabdomyolysis. Lancet Infect Dis 2005, 5:2.
68. Michaelis M., Kleinschmidt M.C., Doerr H.W., et al. Minocycline inhibits West Nile virus replication and apoptosis in human neuronal cells. J Antimicrob Chemother 2007, 60:981-986.
69. Monath T.P., Nystrom R.R., Bailey R.E., et al. Immunoglobulin M antibody capture enzyme-linked immunosorbent assay for diagnosis of St. Louis encephalitis. J Clin Microbiol 1984, 20:784-790.
70. Monath T.P., McCarthy K., Bedford P., et al. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine 2002, 20:1004-1018.
71. Monath T.P., Liu J., Kanesa-Thasan N., et al. A live, attenuated re-combinant West Nile virus vaccine. Proc Natl Acad Sci U S A 2006, 103:6694-6699.
72. Montgomery S.P., Chow C.C., Smith S.W., et al. Rhabdomyolysis in patients with West Nile encephalitis and meningitis. Vector Borne Zoonotic Dis 2005, 5:252.
73. Mostashari F., Bunning M.L., Kitsutani P.T., et al. Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey. Lancet 2001, 358:261-264.
74. Muckenfuss R.S. Clinical observations and laboratory investigations on the 1933 epidemic of encephalitis in St. Louis. Bull N Y Acad Med 1934, 10:444-453.
75. Mukhopadhyay S., Kim B., Chipman P., et al. Structure of West Nile virus. Science 2003, 302:248.
76. Murray K.O., Baraniuk S., Resnick M., et al. Clinical investigation of hospitalized human cases of West Nile virus infection in Houston, Texas, 2002-2004. Vector Borne Zoonotic Dis 2008, 8:167-174.
77. Nasci R.S., Savage H.M., White D.J., et al. West Nile virus in overwintering Culex mosquitoes, New York City, 2000. Emerg Infect Dis 2001, 7:742-744.
78. Nash D., Mostashari F., Fine A., et al. The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med 2001, 344:1807-1814.
79. Paddock C.D., Nicholson W.L., Bhatnagar J., et al. Fatal hemorrhagic fever caused by West Nile virus in the United States. Clin Infect Dis 2006, 42:1527.
80. Parquet M.C., Kumatori A., Hasebe F., et al. West Nile virus-induced bax-dependent apoptosis. FEBS Lett 2001, 500:17-24.
81. Pealer L.N., Marfin A.A., Petersen L.R., et al. Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med 2003, 349:1236-1245.
82. Pepperell C., Rau N., Krajden S., et al. West Nile virus infection in 2002: morbidity and mortality among patients admitted to hospital in southcentral Ontario. Can Med Assoc J 2003, 168:1399-1405.
83. Perelman A., Stern J. Acute pancreatitis in West Nile Fever. Am J Trop Med Hyg 1974, 23:1150.
84. Pergam S.A., DeLong C.E., Echevarria L., et al. Myocarditis in West Nile virus infection. Am J Trop Med Hyg 2006, 75:1232.
85. Petersen L.R., Marfin A.A. West Nile virus: a primer for the clinician. Ann Intern Med 2002, 137:173-179.
86. Petropoulou K.A., Gordon S.M., Prayson R.A., et al. West Nile virus meningoencephalitis: MR imaging findings. AJNR Am J Neuroradiol 2005, 2005(26):1986-1995.
87. Planitzer C.B., Modrof J., Yu M.W., et al. West Nile virus infection in plasma of blood and plasma donors, United States. Emerg Infect Dis 2009, 10:1668-1670.
88. Prince H.E., Tobler L.H., Yeh C., et al. Persistence West Nile virus-specific antibodies in viremic blood donors. Clin Vaccine Immunol 2007, 14:1228-1230.
89. Prince H.E., Lape-Nixon M., Yeh C., et al. Persistence of antibodies to West Nile virus nonstructural protein 5. J Clin Virol 2008, 43:102-106.
90. Pyrgos V., Younus F. High-dose steroids in the management of acute flaccid paralysis due to West Nile virus infection. Scand J Infect Dis 2004, 36:509-512.
91. Rahal J.J., Anderson J., Rosenberg C., et al. Effect of interferon-alpha2b therapy on St. Louis viral meningoencephalitis: clinical and laboratory results of a pilot study. J Infect Dis 2004, 190:1084-1087.
92. Rappole J.H., Derrickson S.R., Hulbalek Z., et al. Migratory birds and the spread of West Nile virus in the western hemisphere. Emerg Infect Dis 2000, 6:319-327.
93. Reimann C.A., Hayes E.B., DiGuiseppi C., et al. Epidemiology of neuroinvasive arboviral disease in the United States, 1999-2007. Am J Trop Med Hyg 2008, 79:974-979.
94. Roehrig J.T., Nash D., Maldin B., et al. Persistence of virus-reactive serum immunoglobulin m antibody in confirmed West Nile virus encephalitis cases. Emerg Infect Dis 2003, 9:376-379.
95. Samuel M.A., Diamond M.S. Pathogenesis of West Nile virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion. J Virol 2006, 80:9349-9360.
96. Samuel M.A., Morrey J.D., Diamond M.S. Caspase 3-dependent cell death of neurons contributes to the pathogenesis of West Nile virus encephalitis. J Virol 2007, 81:2614-2623.
97. Saquib R., Randall H., Chandrakantan A., et al. West Nile virus encephalitis in a renal transplant recipient: the role of intravenous immunoglobulin. Am J Kidney Dis 2008, 52:e19-e21.
98. Sayao A.L., Suchowersky O., Al-Khathaami A., et al. Calgary experience with West Nile virus neurological syndrome during the late summer of 2003. Can J Neurol Sci 2004, 31:194-203.
99. Sejvar J.J. The long-term outcomes of human West Nile virus infection. Clin Infect Dis 2007, 44:1617-1624.
100. Sejvar J.J., Marfin A.A. Manifestations of West Nile neuroinvasive disease. Rev Med Virol 2006, 16:209-224.
101. Sejvar J.J., Haddad M.B., Tierney B.C., et al. Neurologic manifestations and outcome of West Nile virus infection. JAMA 2003, 290:511-515.
102. Sejvar J.J., Leis A.A., Stokic D.S., et al. Acute flaccid paralysis and West Nile virus infection. Emerg Infect Dis 2003, 9:788-793.
103. Sherman-Weber S., Axelrod P. Central diabetes insipidus complicating West Nile encephalitis. Clin Infect Dis 2004, 38:1042.
104. Shi P.-Y., Wong S.J. Serologic diagnosis of West Nile virus infection. Expert Rev Mol Diagn 2003, 3:733-741.
105. Shimoni Z., Niven M.J., Pitlick S., et al. Treatment of West Nile virus encephalitis with intravenous immunoglobulin. Emerg Infect Dis 2001, 7:759.
106. Shrestha B., Diamond M.S. Role of CD8+ T cells in control of West Nile virus infection. J Virol 2004, 78:8312-8321.
107. Smith R.D., Konoplev S., DeCourten-Myers G., et al. West Nile virus encephalitis with myositis and orchitis. Hum Pathol 2004, 35:254-258.
108. Smith H.L., Monath T.P., Pazoles P., et al. Development of antigen-specific memory CD8+ T cells following live-attenuated chimeric West Nile virus vaccination. J Infect Dis 2011, 203:513-522.
109. Smithburn K.C., Burke A.W., Paul J.H. A neurotropic virus isolated from the blood of a native of Uganda. Am J Trop Med Hyg 1940, 20:471-492.
110. Solomon T., Fisher A.F., Beasley D.W.C., et al. Natural and nosocomial infection in a patient with West Nile encephalitis and extrapyramidal movement disorders. Clin Infect Dis 2003, 36:E140-E145.
111. Solomon T., Ooi M.H., Beasley D., Mallewa M. West Nile encephalitis. BMJ 2003, 326:865-869.
112. Southern P.M., Smith J.W., Luby J.P., et al. Clinical and laboratory features of epidemic St. Louis encephalitis. Ann Intern Med 1969, 71:681-689.
113. Tardei G., Ruta S., Chitu V., et al. Evaluation of immunoglobulin M (IgM) and IgG enzyme immunoassays in serologic diagnosis of West Nile virus infection. J Clin Microbiol 2000, 38:2232-2239.
114. Torno M., Vollmer M., Beck C.K. West Nile virus infection presenting as acute flaccid paralysis in an HIV-infected patient: a case report and review of the literature. Neurology 2007, 68:E5-E7.
115. Tunkel A.R., Glaser C.A., Bloch K.C., et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2008, 47:303-327.
116. Tyler K.L. West Nile virus infection in the United States. Arch Neurol 2004, 61:1190-1195.
117. Tyler K.L., Pape J., Goody R., et al. CSF findings in 250 patients with serologically confirmed West Nile virus meningitis and encephalitis. Neurology 2006, 66:361-365.
118. Van der Meulen K.M., Pensaert M.B., Nauwynck H.J. West Nile virus in the vertebrate world. Arch Virol 2005, 150:637-657.
119. Vanlandingham D.L., Schneider B.S., Klingler K., et al. Real-time reverse transcriptase-polymerase chain reaction quantification of West Nile virus transmitted by Culex pipiens quinquefasciatus. Am J Trop Med Hyg 2004, 71:120-123.
120. Venter M., Burt F.J., Blumberg L.N., et al. Cytokine induction after laboratory-acquired West Nile virus infection. N Engl J Med 2009, 360:1260-1262.
121. Verma S., Lo Y., Chapagain M., et al. West Nile virus infection modulates human brain microvascular endothelial cells tight junction proteins and cell adhesion molecules: transmigration across the in vitro blood-brain barrier. Virology 2009, 385:425-433.
122. Wang Y., Lobigs M., Lee E., et al. CD8 T cells mediate recovery and immunopathology in West Nile virus encephalitis. J Virol 2003, 77:13323-13334.
123. Wang T., Town T., Alexopoulou L., et al. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med 2004, 10:1366-1373.
124. Wang P., Dai J., Bai F., et al. Matrix metalloproteinase 9 facilitates West Nile virus entry into the brain. J Virol 2008, 82:8978-8985.
125. Wasay M., Diaz-Arrastia R., Suss R.A., et al. St Louis encephalitis: a review of 11 cases in a 1995 Dallas, Tex, epidemic. Arch Neurol 2000, 57:114-118.
126. Watson J.T., Pertel P.E., Jones R.C., et al. Clinical characteristics and functional outcomes of West Nile fever. Ann Intern Med 2004, 141:360-365.
127. Weaver S.C., Reisen W.K. Present and future arboviral threats. Antiviral Res 2010, 85:328-345.
128. Weiss D., Carr D., Kellachan J., et al. Clinical findings of West Nile virus infection in hospitalized patients, New York and New Jersey, 2000. Emerg Infect Dis 2001, 7:654-658.
129. Yakub I., Lillibridge K.M., Moran A., et al. Single nucleotide polymorphisms in genes for 2'-5'-oligoadenylate synthetase and RNase L inpatients hospitalized with West Nile virus infection. J Infect Dis 2005, 192:1741-1748.
130. Yim R., Posfay-Barbe K.M., Nolte D., et al. Spectrum of clinical manifestations of West Nile virus infection in children. Pediatrics 2004, 114:1673-1675.